Sometimes called “gas station heroin,” the products are usually marketed as energy shots or cognitive supplements but ...

Morningstar brands and products Company Portfolio ...

Starting June 30, 2025, all car seats sold in the U.S. must meet new federal safety standards aimed at improving protection ...

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

"With these results, we are pleased to demonstrate that restoring hemodynamic modulation of the artery translates to lasting clinical outcomes, elevating the level of care for patients,” said Motasim ...

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...

(Circulation: Cardiovascular Interventions) The DynamX coronary bioadaptor continued to perform well 3 years into the BIOADAPTOR trial, as announced by Elixir Medical. CytoSorbents shared more ...

Elixir Medical’s DynamX [Image courtesy of Elixir Medical] Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system.